Neurotech Pharma's cell therapy Encelto has become the first FDA-approved treatment for idiopathic macular telangiectasia ...

J&J is already seeing strong sales growth for its treatment-resistant depression (TRD) and MDD therapy Spravato (esketamine), ...

The results of the Intuition Brain Health study – sponsored by Biogen and supported by Apple – show the feasibility of using ...

Investing in women's health isn't just ethically sound; it's smart business. Women represent half the global population, and ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Big data is transforming this approach by providing healthcare organisations with a deeper understanding of patient ...

Johns Hopkins surgeon and writer Dr Martin Makary, President Donald Trump's pick to lead the FDA, faced a grilling today by ...

The company confirmed this morning that NICE has taken the "unusual decision" to hold a third appraisal committee meeting as ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Novo Nordisk has launched a direct-to-consumer (DTC) option for uninsured or under-insured people wanting to access its GLP-1 ...

GUB014295 is a subcutaneously administered long-acting amylin agonist that also stimulates calcitonin receptors, according to ...

It takes around seven years to develop a new drug and bring it to market. With the advent of GenAI, businesses in the life ...